Amplitude Surgical – H1 2021-22: Revenue of €48.1m, +3.9% at constant exchange rates

VALENCE, France–(BUSINESS WIRE)–Regulatory news:

Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME plans), a leading French player in the market for surgical technologies for lower limb orthopedics, announces its sales for the first half of its financial year 2021-22.

Olivier Jallabert, CEO of Amplitude Surgicalcommented : “During the first half of our 2021-22 fiscal year, Amplitude Surgical recorded a 3.9% increase in revenue at constant currencies. Knee and hip activity remained stable compared to the previous year and continues to be negatively affected by the public health situation related to the COVID-19 pandemic, with new health restrictions and operations canceled as well as reduced availability of operating theaters and medical personnel. Novastep, for its part, continued its development and now represents approximately 16.4% of the Group’s total sales, with growth of nearly 33% over the period.

Sales by activity

H1 2021-22 revenue

31/12/2021

31/12/2020

Change in progress

exchange rate

Change to

constant

exchange rate

In thousands of euros – IFRS

Knee and hip activity

40 187

40,072

0.3%

-0.3%

Feet and ankles (Novastep)

7,912

5,838

35.5%

33.1%

Total

48,099

45,910

4.8%

3.9%

Q2 2021-22 sales

31/12/2021

31/12/2020

Change in progress

exchange rate

Change to

constant

exchange rate

In thousands of euros – IFRS

Knee and hip activity

23,150

20,892

10.8%

10.3%

Feet and ankles (Novastep)

4,760

3,435

38.6%

34.7%

Total

27,910

24,327

14.7%

13.7%

In the first half of its 2021-22 financial year (from July to December 2021), Amplitude achieved revenue of €48.1 million, up 4.8% in actual terms and 3.9% at exchange rates. constant changes.

  • Knee and hip activity was stable with sales up 0.3% in actual terms and down 0.3% at constant exchange rates. After a first quarter down on the previous year, notably impacted by lower availability of operating theaters in France, the second quarter saw a recovery with growth of 10.3%, with fewer restrictions linked to the situation. health than the previous year. Nevertheless, the health situation and the reduced availability of operating theaters and medical personnel continue to have a considerable negative impact on activity;
  • Novastep, innovative solutions for foot and ankle surgery, generated strong growth over the half-year with revenue of €7.9 million (+33.1% at constant exchange rates), driven by the United States . Novastep’s activity now represents 16.4% of the Group’s total sales.

Sales by geographic area

H1 2021-22 revenue

31/12/2021

31/12/2020

Change in progress

exchange rate

Change to

constant

exchange rate

In thousands of euros – IFRS

France

30,502

29,615

3.0%

3.0%

International

17,597

16,295

8.0%

5.6%

of which subsidiaries

13,825

12,457

11.0%

7.9%

of which distributors

3,771

3,839

-1.7%

-1.7%

Total

48,099

45,910

4.8%

3.9%

Q2 2021-22 sales

31/12/2021

31/12/2020

Change in progress

exchange rate

Change to

constant

exchange rate

In thousands of euros – IFRS

France

18,241

15,468

17.9%

17.9%

International

9,669

8,859

9.1%

6.4%

of which subsidiaries

7,550

6,938

8.8%

5.3%

of which distributors

2,119

1,921

10.3%

10.3%

Total

27,910

24,327

14.7%

13.7%

By geographic area, sales evolved as follows:

  • On the french market, in total, the activities of Amplitude Surgical recorded sales growth of 3.0% over the last half-year to 30.5 million euros, representing 63.4% of the Group’s total sales. The activity continues to be negatively affected by the health situation linked to COVID-19, the growth shown being mainly due to the different level of impact of the pandemic between the two years;

  • That of the Group international activity achieved a turnover of €17.6 million, up 8.0% in real terms and 5.6% at constant exchange rates thanks to the international subsidiaries. The Group’s subsidiaries recorded growth of 7.9% at constant exchange rates to €13.8 million thanks to the strong growth of Novastep’s foot and ankle business in the United States. Business with the Group’s distributors is down 1.7% with revenue of €3.8 million;

  • Surgical Amplitude direct business (French market and international subsidiaries), which represent nearly 92% of the Group’s total revenue, generated growth of 4.5% at constant exchange rates.

Next financial press release

2021-22 half-year results, Wednesday March 23, 2022, after market close.

About Amplitude Surgical

Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main pathologies of the hip, knee and extremities, and in particular foot and ankle surgery. Amplitude Surgical develops, in close collaboration with surgeons, numerous innovations with high added value in order to best meet the needs of patients, surgeons and healthcare establishments. A benchmark player in France, Amplitude Surgical is expanding abroad through its subsidiaries and a network of distributors and exclusive agents distributing its products in more than 30 countries. Amplitude Surgical operates in the lower limbs market through its Novastep subsidiaries in France and the United States. As of June 30, 2021, Amplitude Surgical has 443 employees and generates revenue of nearly €95.5 million.